OVISEHomo sapiens (Human)Cancer cell line
Quick Overview
OVISE is a human ovarian cancer cell line used in research for studying high-grade serous ovarian cancer.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3116 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pelvis, innominate bone[UBERON:UBERON_0001272] |
Donor Information
| Age | 40 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | asian |
Disease Information
| Disease | Clear cell adenocarcinoma of the ovary |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | Clear Cell Ovarian Cancer |
| OncoTree Code | CCOV |
DepMap Information
| Source Type | HSRRB |
|---|---|
| Source ID | ACH-000527_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | PIK3CA | p.Cys420Arg (c.1258T>C) | Heterozygous | - | from parent cell line JIMT-1 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Velculescu V.E., Scharpf R.B.
Cell Rep. 25:2617-2633(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Nat. Commun. 7:12645.1-12645.14(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data Brief 7:1302-1305(2016).
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
J. Proteomics 139:77-83(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.
Itamochi H., Bodenmiller B., Erler J.T., Turk B.E., Linding R.
Cell 163:202-217(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Type-specific cell line models for type-specific ovarian cancer research.
Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
PLoS ONE 8:E72162-E72162(2013).
Evaluating cell lines as tumour models by comparison of genomic profiles.
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Nat. Commun. 4:2126.1-2126.10(2013).
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Miyazaki K.
Hum. Pathol. 43:2197-2206(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";
Anderson M.L., Matzuk M.M.
Mol. Endocrinol. 24:447-463(2010).
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Hirohashi S., Inazawa J., Imoto I.
Cancer Res. 67:7095-7105(2007).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.
Hirahara F., Shirotake S.
Cancer Lett. 162:39-48(2001).
Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.
Kitamura H., Minaguchi H.
Br. J. Cancer 76:829-835(1997).
Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
Minaguchi H.
Gynecol. Oncol. 57:33-46(1995).
Establishment and characterization of human ovarian clear cell carcinoma cell line, OVISE.
Nakazawa T., Gorai I., Doi C., Hirahara F., Minaguchi H.
Nihon Rinsho Saibo Gakkai Zasshi 31:966-972(1992).